# US 2018/0021367 A1 · Use of a mixture of modified glucose polymers for reducing tumor metastasis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021367 A1
- Document ID: US20180021367A1
- Status: Published application
- Kind: A1
- Application number: 15/547,283
- Filed: 2016-02-01
- Published: 2018-01-25
- Earliest claimed: 2015-01-30
- Applicants: Fresenius Kabi Deutschland GmbH
- Inventors: Bernd Sundermann; Lars Walz; Silke Baasner; Frank Nocken; Christoph Meyer
- Web page: https://patentgrep.com/patent/US20180021367A1

## CPC

- A61K 31/721: Dextrans
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/01: Hydrocarbons
- A61K 31/718: Starch or degraded starch, e.g. amylose, amylopectin
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein is a solution, in particular a pharmaceutically acceptable solution, comprising icodextrin and hydroxyalkyl starch (HAS) that can be used in methods of preventing metastasis formation and/or relapse by administration to a body cavity of a subject afflicted with cancer. Also disclosed is a kit comprising icodextrin and HAS in pre-weighed amounts and a pharmaceutically acceptable means of dissolving the same. Also disclosed is a device comprising a pharmaceutically acceptable solution and means for administering the same.

## Claims

### Claim 1

A pharmaceutically acceptable solution comprising icodextrin and hydroxyalkyl starch (HAS), wherein said icodextrin is present at a concentration of from 1 to 7.5% (w/v) and wherein said HAS is present at a concentration of from 1 to 15% (w/v).

### Claim 2 (depends on 1)

The pharmaceutically acceptable solution for use of claim 1, wherein said HAS is hydroxyethyl starch (HES).

### Claim 3 (depends on 1)

The pharmaceutically acceptable solution of claim 1, wherein said HAS has a molar substitution (MS) value in the range of from 0.1 to 3.

### Claim 4 (depends on 1)

The pharmaceutically acceptable solution of claim 1, wherein said HAS has an average molecular weight (Mw) of from 70 to 150 kDa.

### Claim 5 (depends on 1)

The pharmaceutically acceptable solution of claim 1, wherein said icodextrin has an average molecular weight (Mw) of from 10 to 20 kDa.

### Claim 6 (depends on 1)

The pharmaceutically acceptable solution of claim 1, wherein said icodextrin is present at a concentration of from 3 to 5% (w/v) and/or wherein said HAS is present at a concentration of from 7.5 to 12.5% (w/v).

### Claim 7 (depends on 1)

The pharmaceutically acceptable solution of claim 1, wherein the total concentration of icodextrin and HAS is from 7 to 15% (w/v).

### Claim at position 8

-10. (canceled)

### Claim 11

A kit comprising icodextrin and HAS in pre-weighed amounts and a pharmaceutically acceptable means of dissolving the same.

### Claim 12 (depends on 1)

A device comprising the pharmaceutically acceptable solution of claim 1 and means for administering the solution.

### Claim 13

A pharmaceutically acceptable solution comprising icodextrin and hydroxyalkyl starch at a total concentration in the range of from 1 to 20% (w/v), wherein the weight ratio of the icodextrin relative to the hydroxyalkyl starch is in the range of from 0.05:1 to 5:1.

### Claim 14 (depends on 13)

The pharmaceutically acceptable solution of claim 13, wherein the total concentration of icodextrin and hydroxyalkyl starch is in the range of from 5 to 16% (w/v).

### Claim 15 (depends on 14)

The pharmaceutically acceptable solution of claim 14, wherein the total concentration of icodextrin and hydroxyalkyl starch is in the range of 14%±1% (w/v) and wherein the weight ratio of the icodextrin relative to the hydroxyalkyl starch is in the range of from 0.3:1 to 0.5:1.

### Claim 16

A method for preventing metastasis formation and/or relapse in a subject afflicted with cancer, the method comprising administering a pharmaceutically acceptable solution comprising icodextrin at a concentration of from 1% to 7.5% (w/v) and hydroxyalkyl starch (HAS) at a concentration of from 1% to 15% (w/v) to a body cavity of the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein preventing metastasis formation and/or relapse in a subject is preventing metastasis formation and/or relapse in the body cavity of the subject.

### Claim 18 (depends on 16)

The method of claim 16, wherein the pharmaceutically acceptable solution comprises icodextrin at a concentration of from 3% to 5% (w/v) and hydroxyalkyl starch (HAS) at a concentration of from 5% to 12.5% (w/v).

### Claim 19 (depends on 16)

The method of claim 16, wherein the total concentration of icodextrin and hydroxyalkyl starch is in the range of from 7.5% to 15% (w/v).

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The pharmaceutically acceptable solution of claim 1, wherein the pharmaceutically acceptable solution comprises icodextrin at a concentration of from 3% to 5% (w/v), and hydroxyalkyl starch (HAS) at a concentration of from 5% to 12.5% (w/v).

### Claim 22

A composition comprising icodextrin and hydroxyalkyl starch (HAS).

### Claim 23 (depends on 22)

The composition according to claim 22, wherein the weight ratio of the icodextrin relative to the hydroxyalkyl starch is in the range of from 0.3:1 to 0.5:1.

### Claim 24 (depends on 16)

The method of claim 16, wherein
the cancer is ovarian cancer, ovarian carcinoma, stomach cancer, lung cancer, pancreas cancer, bladder cancer, liver cancer, colorectal cancer, breast cancer, or colon cancer;
metastasis formation and/or relapse is prevented in the abdominal cavity; and/or
the pharmaceutically acceptable solution is administered postoperatively, intraoperatively, or preoperatively.
